Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
AssigneeEos Biotechnology, Inc.
InventorsEdward Yat Wah Tom, Albert Zlotnik
Life of this patent
Estimating the term…
Abstract
Described herein are genes whose expression are up-regulated or down-regulated during the course of Hepatitis C infection, or distinction between treatment response. Related methods and compositions that can be used for diagnosis and treatment of Hepatitis C infection and/or its secondary consequences are disclosed. Also described herein are methods that can be used to identify modulators of Hepatitis C infection and/or its secondary consequences.
Claims24
A method of detecting an RNA transcript associated with Hepatitis C infection in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1A-15.
An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1A-15.
An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1A-15.
A method for identifying a compound that modulates a Hepatitis C infection-associated polypeptide, the method comprising the steps of:
- a) contacting the compound with a Hepatitis C infection-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1A-15 and
- b) determining the functional effect of the compound upon the polypeptide.
A drug screening assay comprising the steps of
- a) administering a test compound to a mammal suffering from Hepatitis C infection and its secondary consequences or a cell isolated therefrom
- b) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1A-15 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of Hepatitis C infection and its secondary consequences.
Dependencies are inferred from the claim text.